Effect Of Lipid Lowering Drugs On Serum Lipoprotein-Related Phospholipase A₂ Levels In Patients With Coronary Heart Disease

Objective:To investigate the effect of statin lipid lowering drugs on serum lipoprotein-associated phospholipase A₂ levels in patients with coronary heart disease.Methods:The patients who were admitted to the Cardiovascular Department of Yongzhou Central Hospital（Cold Water Beach Hospital）from December 2017 to December 2018 and diagnosed as coronary heart disease by coronary angiography were selected as subjects.All observers were given secondary prevention of coronary heart disease,all observers were tested of serum lipoprotein-associated phospholipase A₂（Lp-PLA₂）levels,patients were followed for three months,all patients were retested for serum Lp-PLA₂levels after three months,there will be a complete data 107 Patients with coronary heart disease were analyzed and divided into two groups according to different types of coronary heart disease:group A was patients with acute coronary syndrome,group B was patients with chronic coronary disease,and two groups were compared for three months.The changes of serum Lp-PLA₂levels before and after treatment and the difference between the two groups were statistically significant.According to the different statin lipid-lowering drugs used by patients,they were divided into two groups:group C and group D.Group C was simvastatin group,group D was atorvastatin group.Baseline serum Lp-PLA₂ level and lipid-lowering drug treatment were compared.The difference in serum Lp-PLA₂ results before and after March was statistically significant.Results:1.There were no significant differences in gender,lipid-lowering drugs,past medical history（diabetes,hypertension）,smoking status and drinking status between group A and group B（P>0.05）.The age,BMI and systolic blood pressure of the two groups were different.There was no significant difference in diastolic blood pressure,heart rate and total bilirubin（P>0.05）.There were no significant differences in gender,coronary heart disease classification,past medical history（diabetes,hypertension）,smoking status and drinking status between group C and group D（P>0.05）.The age,BMI and systolic blood pressure of the two groups were different.There was no significant difference in diastolic blood pressure,heart rate and total bilirubin（P>0.05）.2.There were significant differences in serum Lp-PLA₂ levels between group A before and after treatment（P<0.05）.There was significant difference in serum Lp-PLA₂ levels between group B before and after treatment（P<0.05）.Serum Lp-PLA₂ of the two groups before and after treatment the difference was statistically significant（T=2.564,P=0.005）.3.There were no significant differences in total cholesterol,triglyceride,low-density lipoprotein and high-density lipoprotein between group A and group B（P>0.05）.After treatment,total cholesterol,triglyceride,low density lipoprotein and the difference of high-density lipoprotein was statistically significant（P<0.05）.The difference of total cholesterol between the two groups before and after treatment was statistically significant（P<0.05）.Before and after treatment in group A,the difference in total cholesterol was statistically significant（T=10.103,P<0.001）,the difference in triglyceride was statistically significant（T=5.029,P<0.001）,and the difference in low-density lipoprotein was Statistically significant（T=5.160,P<0.001）,high-density lipoprotein differences were statistically significant（T=5.102,P<0.001）.Before and after treatmentin in group B,the difference of total cholesterol was statistically significant（T=11.398,P<0.001）,the difference of triglyceride was statistically significant（T=7.059,P<0.001）,and the difference of low density lipoprotein was Statistically significant（T=7.290,P<0.001）,high-density lipoprotein was statistically significant（T=6.905,P<0.001）.4.There was no significant difference in serum Lp-PLA₂ levels between group C and group D（T=1.351,P>0.05）.There was a statistically significant difference in serum Lp-PLA₂ levels between the two groups（T=2.747,P<0.05）,the difference of serum Lp-PLA₂ levels between the two groups before and after treatment was statistically significant（P<0.05）.There were significant differences in serum Lp-PLA₂ levels between the group C and the patients before and after treatment（T=7.455,P<0.001）.There was significant difference in serum Lp-PLA₂ levels between the group D and the patients before and after treatment（T=8.985,P<0.001）.5.There was no significant difference in creatinine,alanine aminotransferase,aspartate aminotransferase and blood glucose between group A and group B（P>0.05）.There were no significant differences in creatinine,alanine aminotransferase,aspartate aminotransferase and blood glucose between group C and group D（P>0.05）.Conclusions:1.Statins can reduce serum lipoprotein-associated phospholipase A₂ levels in patients with coronary heart disease,and lower serum lipoprotein related phospholipase A₂ levels in patients with acute coronary syndrome than those with chronic myocardial ischemic syndrome.2.Atorvastatin is superior to simvastatin in lowering serum lipoprotein-associated phospholipase A₂ levels.